Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial - PubMed
11 hours ago
- #Cardiovascular disease
- #Lipoprotein apheresis
- #Pelacarsen
- The Lp(a)FRONTIERS APHERESIS trial investigated pelacarsen's effect on reducing lipoprotein apheresis (LA) need in patients with elevated lipoprotein(a) [Lp(a)] and cardiovascular disease (CVD).
- Patients with Lp(a) >60 mg/dl and prior LA sessions were randomized to pelacarsen 80 mg or placebo every 4 weeks for 52 weeks.
- Pelacarsen significantly reduced LA session rates (0.16 vs. 0.93 in placebo) and increased LA avoidance (hazard ratio: 88.3).
- At week 52, pelacarsen showed a -72% placebo-adjusted Lp(a) reduction from baseline (P < .0001).
- Treatment was well-tolerated, with mild injection site erythema being the most common adverse event in the pelacarsen group (38.5%).
- Pelacarsen is effective in reducing LA need for patients with elevated Lp(a) and established CVD.